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Abstract
Background Neuroendocrine tumors typically arise from pancreatic (PNET) vs. gastrointestinal or thoracic origins (non-PNET).
The impact of primary tumor site on long-term prognosis following resection of neuroendocrine liver metastasis (NELM)
remains poorly defined. The objective of the current study was to define the association of primary tumor location on prognosis
of patients undergoing curative intent liver resection for NELM.
Methods Between 1990 and 2014, 421 patients who underwent resection of NELM were identified from a multi-institutional
database. Clinicopathological characteristics, operative details, and outcomes were stratified and analyzed by location of the
primary tumor (PNET vs. non-PNET). A propensity score-matched analysis was utilized to assess the impact of primary tumor
location on long-term survival.
Results Among the 421 patients, 197 (46.8%) patients had NELM from a PNET primary while 224 (53.2%) had a non-PNET
primary (small bowel, n = 145; rectal, n = 10; bronchial, n = 22; other, n = 47). There were no differences in tumor burden and
tumor site, while presence of extrahepatic disease was more common among patients with non-PNET NELM (extrahepatic
disease, PNET NELM, n = 11 27.5% vs. non-PNET NELM, n = 29 72.5%; p = 0.010). Patients with PNET NELM were more
likely to have non-functional disease compared with patients who had non-PNETNELM (non-functional, PNETNELM, n = 117
54.9% vs. non-PNET NELM, n = 96 45.1%; p = 0.011). On the final pathological specimen of the resected NELM, patients with
PNET NELM were more likely to have a moderately differentiated tumor (59.3%), while patients with non-PNET NELM were
more likely to have a poorly differentiated tumor (67.8%) (p = 0.005). Patients with PNETNELM had a worse 5-year DFS and 5-
year OS compared with patients who had non-PNETNELM (DFS, PNET 36.2% vs. non-PNET 55.2%; p = 0.001 and OS, PNET
79.5% vs. non-PNET 83.4%; p = 0.008). After propensity score matching, both 5-year DFS and 5-year OS of the PNETand non-
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PNET groups were comparable (DFS, PNET 46.2% vs. non-PNET 55.9%; p = 0.22 and OS, PNET 81.5% vs. non-PNET 84.3%;
p = 0.19).
Conclusion PNET patients more often present with non-functional NELM and moderately differentiated tumors. On propensity-
matched analysis, factors such as extrahepatic disease and tumor grade, but not primary tumor location, were associated with
prognosis of patients undergoing curative intent liver surgery for NELM.
Keywords NELM . Surgery . PNET . Pancreatic
neuroendocrine tumor . Neuroendocrine liver metastasis
Introduction
Neuroendocrine tumors (NET) are a heterogeneous group of
rare and typically slow-growing tumors with varied histologic
features that arise most commonly from the pancreas and the
luminal gastrointestinal tract.
1
NET are often hormone-
secreting tumors, causing a wide range of hormonal syn-
dromes, sometimes characterized by severe symptoms that
can negatively impact quality of life.
2
Specifically, in a subset
of patients with functional tumors, NETcan cause debilitating
hormonal symptoms, such as flushing, palpitations, as well as
diarrhea.
3–8 Thus, treatment goals for NET should include
both prolongation of survival, as well as NET-related symp-
tom alleviation.
2
Although the natural history of NET is often indolent and
can be characterized by slow progression,
9
up to 60–80% of
patients can present with synchronous or develop
metachronous neuroendocrine liver metastasis (NELM) dur-
ing the course of their disease. The presence of metastatic
disease, perhaps not surprisingly, has been reported to be
one of the strongest predictors of survival.
10–12 Indeed, the
5-year overall survival (OS) of patients with NELM ranges
from 13 to 54 vs. 75–99% for patients with NET who do not
have NELM.
12–14 Since many patients with NELM die of pro-
gressive liver disease,
1
the utilization of liver directed thera-
pies, including hepatic resection, remains central to the treat-
ment of patients with NELM.
15–17 Following liver resection,
while 5-year survival can be as high as 60–75%, recurrence is
much more common with up to 75–90% of patients
experiencing a recurrence within 5 years.
15
In fact, our group
had previously reported that the probability of being Bcured^
from NELM by liver surgery was only 44%.
18
Multiple clinicopathological factors have been proposed as
having an impact on the long-term prognosis of patients fol-
lowing resection of NELM. In particular, we recently reported
a non-mixture cure fraction statistical model to estimate sur-
vival following resection.
18
The model identified type of NET,
grade of tumor differentiation, and extent of liver involvement
as being independent predictors of cure. In a separate study of
the Italian Neuroendocrine Liver Metastasis Database,
Ruzzenente et al. identified number of NELM, tumor size,
and Ki-67 index as prognostic factors associated with the
prognosis of patients undergoing liver resection of NELM.
4
Moreover, Mayo et al. reported that hormonal status and pres-
ence of extrahepatic disease were associated with long-term
survival, while R0 resection was associated with improved
outcomes only among patients with functional tumors.
19
Despite these previous studies, the impact of primary tumor
site on long-term prognosis following resection of NELM
remains poorly defined. As such, the objective of the current
study was to assess the impact of pancreatic (PNET) vs. gas-
trointestinal or thoracic (non-PNET) primary tumor site on the
prognosis of patients undergoing curative intent hepatic resec-
tion of NELM.
Materials and Methods
Patient Demographic and Clinical Data
Patients were identified from a neuroendocrine liver metasta-
ses database that included 421 patients who underwent multi-
modal treatments for NELM from 1990 to 2014 at one of
seven major hepatobiliary institutions (Johns Hopkins
Hospital, Baltimore, MD; Stanford University, Stanford,
CA; Washington University School of Medicine, St Louis,
MO; University of Virginia, Charlottesville, Virginia;
Scientific Institute San Raffaele, Vita-Salute San Raffaele
University, Milan, Italy; Curry Cabral Hospital, Lisbon,
Portugal; Winship Cancer Institute, Emory University,
Atlanta, GA). Only patients who had either simultaneous or
staged surgical resection of both the primary tumor and the
liver metastases were included in the study cohort. Patients
who received only non-surgical treatments (e.g., emboliza-
tion, ablation, etc.) and/or did not undergo surgical resection
of the primary NET were excluded from the analyses. The
Institutional Review Board of all the participating institutions
approved the study.
Standard demographic and clinicopathologic data were
collected including age, gender, disease functional status, liver
tumor burden, liver tumor site, and primary tumor lymph
node status, margin status, grade of differentiation, and
presence of extrahepatic disease. According to the 2010
WHO grading system, tumor grade was classified as well
(G0), moderately (G1), or poorly (G3) differentiated; if histo-
logic grade varied in a specific specimen, the Bworst^ grade
was used as the index tumor grade.
20
A R0 resection was
defined as the absence of macroscopic or microscopic disease
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at the surgical margin, while a R1 resection was classified as
microscopic presence of tumor and R2 was classified as mac-
roscopic presence of tumor (debulking). Nodal status was
ascertained based on final pathologic assessment. Treatment-
related variables were also included, such as type of treatment
before surgery, type of liver surgery, receipt of intraoperative
ablation, and receipt of adjuvant treatment. Data on type of
surgery were collected with major hepatic resection defined as
resection of at least three full Couinaud segments.
21
Hepatic
resection was performed with a variety of techniques.
22
NELM
primary NET sites included pancreas (PNET), gastrointestinal
tract (G-NET), and tracheo-bronchopulmonary complex (TB-
NET) neuroendocrine tumors. For the purposes of analyses,
primary tumor site was categorized as pancreatic (PNET) vs.
gastrointestinal or thoracic (non-PNET).
Statistical Analysis
Continuous variables were summarized as medians with
interquartile ranges (IQR) while categorical variables
were reported as whole numbers and percentages. The
primary outcome of interest was OS; the secondary out-
come was disease-free survival (DFS). OS was defined as
the time interval between the date of surgery and the date
of death. Time was censored at the date of last follow-up
for living patients. DFS was defined as the time interval
between the date of surgery and the date of recurrence.
Time was censored at the date of last follow-up for pa-
tients who were noted to be free of disease. Date of last
follow-up and vital status were collected for all patients.
Clinicopathological characteristics, operative details, and
outcomes were stratified and analyzed by location of the
primary tumor ((PNET) vs. (non-PNET)).
To account for any potential residual confounding
when assessing the effect of NET primary site on surviv-
al, propensity scores were estimated using a logistic re-
gression model with binary outcomes specified as PNET
vs. non-PNET. Gender, grade of tumor differentiation,
lymph node status, functional status, synchronous disease,
preoperative treatment, liver involvement, extrahepatic
disease, margin status, and adjuvant treatment were in-
cluded as independent variables in the logistic regression
model. A caliper width of 0.1 times the standard deviation
of the propensity score was used for matching; one-to-one
matching without replacement was used to identify 132
PNET and 132 non-PNET matched patients. The degree
of covariate imbalance in unmatched and matched sam-
ples was measured using the standardized (mean and pro-
portion) differences. All analyses were carried out with
STATA version 12.0 (StataCorp, College Station, TX).
All tests were two-sided and a p value <0.05 was consid-
ered statistically significant.
Results
Demographic and Clinicopathologic Characteristics
A total of 421 patients who underwent hepatic resection for
NELM met the inclusion criteria and were included in the
study cohort (Table 1). Median patient age was 58 years (in-
terquartile range, 49.0–67.9) and half of patients were female
(n = 219, 52.0%). The tumor was well, moderately, and poorly
differentiated in 173 (54.4%), 86 (27.0%), and 59 (18.6%),
respectively. Lymph node metastasis occurred in 213 (56.5%)
patients. Liver metastases were synchronous in 259 (61.8%)
patients and metachronous in 160 (38.2%) patients. The ma-
jority of patients (n = 285, 76.0%) did not receive any addi-
tional treatment before hepatectomy, while 63 (16.8%) and 27
(7.2%) patients had received octreotide or chemotherapy, re-
spectively. NELM involved >75%, 75–50%, 50–25%, and
>25% of the liver in 190 (49.2%), 120 (31.1%), 62 (16.1%),
and 14 (3.6%) patients, respectively. NELM disease was bi-
lateral in 217 (57.3%) patients; extrahepatic disease was diag-
nosed in 40 (9.5%) patients. At the time of surgery, intraoper-
ative tumor ablations were performed in 90 (21.5%) patients.
Final surgical margin status was R0, R1, and R2 in 279
(68.9%), 95 (23.5%), and 31 (7.6%), respectively. The major-
ity of patients (n = 177, 56.9%) did not receive any adjuvant
treatment, while 97 (31.2%) and 37 (11.9%) patients received
post-operative octreotide and chemotherapy, respectively.
The primary NET was pancreatic in 197 (46.8%) patients
vs. gastrointestinal tract or other organs (i.e., tracheo-
bronchopulmonary, lung, etc.) in 224 (53.2%) patients. As
expected, there were differences in the baseline clinicopatho-
logical characteristics of patients with NELM from PNET vs.
non-PNET primary tumors.While there were no differences
in age and gender, patients with PNET-derived NELM
were more likely to have non-functional disease compared
with patients who had non-PNET-derived NELM
(non-functional, PNET NELM, n = 117 54.9% vs. non-
PNET derived NELM, n = 96 45.1%; p = 0.011). There
were no differences in tumor burden and tumor site, while
presence of extrahepatic disease was more common
among patients with non-PNET-derived NELM (extrahe-
patic disease, PNET-derived NELM, n = 11 27.5% vs.
non-PNET derived NELM, n = 29 72.5%; p = 0.010).
Presence of synchronous primary tumor and NELM was
comparable among patients with a primary pancreatic
NET and other primary NET. There was also no differ-
ence in terms of type of surgery; 94 (43.7%) patients with
PNET-derived NELM underwent a major liver resection
compared with 121 (56.3%) patients with non-PNET-
derived NELM (p = 0.20). Intraoperative tumor ablation
was common among both groups (PNET-derived NELM
48.9% vs. non-PNET-derived NELM 51.1%). On the final
pathological NELM specimen, patients with PNET-
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derived NELM were more likely to have a moderately
differentiated tumor (59.3%), while patients with non-
PNET-derived NELM were more likely to have a poorly
differentiated tumor (67.8%) (p = 0.005). Patients with
PNET-derived NELM were slightly less likely to have lymph
node metastasis (43.7%) compared with patients who had non-
PNET-derived NELM (56.3%) (p = 0.09). Margin status was
comparable between the two groups (p = 0.96). Among patients
who received any type of adjuvant treatment, octreotide was
more commonly administered to patients with non-PNET-
derived NELM, while chemotherapy was more common
among patients with PNET-derived NELM (p < 0.001).








Patients 197 224 –
Age, median (IQR) 58 years (49.0–67.9) 58 years (48–69) 59 years (50–67) 0.96
Gender 0.38
Female 219 (52.0) 107 (48.9) 112 (51.1)
Male 202 (48.0) 90 (44.6) 112 (55.4)
Functional status 0.011
Non-functional 213 (63.8) 117 (54.9) 96 (45.1)
Functional 121 (36.2) 49 (40.5) 72 (59.5)
NA/missing 87 31 56
Grade of differentiation 0.005
Well 173 (54.4) 77 (44.5) 96 (55.5)
Moderate 86 (27.0) 51 (59.3) 35 (40.7)
Poor 59 (18.6) 19 (32.2) 40 (67.8)
NA/missing 103 50 53
Primary tumor lymph node status 0.09
N0 164 (43.5) 86 (52.4) 78 (47.6)
N1 213 (56.5) 93 (43.7) 120 (56.3)
NA/missing 44 18 26
Synchronous disease 0.71
No 160 (38.2) 73 (45.6) 87 (54.4)
Yes 259 (61.8) 123 (47.5) 136 (52.5)
NA/missing 2 1 1
Treatment before liver surgery 0.005
None 285 (76.0) 127 (44.6) 158 (55.4)
Octreotide 63 (16.8) 25 (39.7) 38 (60.3)
Chemotherapy 27 (7.2) 21 (77.7) 6 (22.3)
NA/missing 46 24 22
Liver involvement 0.19
>25% 14 (3.6) 5 (35.7) 9 (64.3)
25–50% 62 (16.1) 28 (45.2) 34 (54.8)
50–75% 120 (31.1) 45 (37.5) 75 (62.5)
<75% 190 (49.2) 94 (49.5) 96 (50.5)
NA/missing 35 25 10
Location 0.21
Unilobar 162 (42.7) 83 (51.2) 79 (48.8)
Bilobar 217 (57.3) 97 (44.7) 120 (55.3)
NA/missing 42 17 25
Intraoperative tumor ablation 0.67
No 328 (78.5) 152 (46.3) 176 (53.7)
Yes 90 (21.5) 44 (48.9) 46 (51.1)
NA/missing 3 1 2
Extrahepatic disease 0.01
No 381 (90.5) 186 (48.8) 195 (51.2)
Yes 40 (9.5) 11 (27.5) 29 (72.5)
Margin status 0.96
R0 279 (68.9) 128 (45.9) 151 (54.1)
R1 95 (23.5) 43 (45.3) 52 (54.7)
R2 31 (7.6) 15 (48.4) 16 (51.6
NA/missing 16 11 5
Adjuvant therapy <0.001
None 177 (56.9) 100 (56.5) 77 (43.5)
Octreotide 97 (31.2) 30 (30.9) 67 (69.1)
Chemotherapy 37 (11.9) 30 (81.1) 7 (18.9)
NA/missing 110 37 73
Disease-free survival, 5 years (95% CI) 46.2% (40.3–51.9) 36.2% (28.2–44.3) 55.2% (46.8–62.8) 0.001
Overall survival, 5 years (95% CI) 81.5% (76.7–85.4) 79.5% (72.2–85.1) 83.4% (76.6–88.4) 0.008
NA/missing not available/missing
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Long-TermOutcomes of Patients with NELM fromPNET
and Non-PNET
Within a median follow-up of 4.6 years, the 1-, 3-, and 5-
year DFS was 80.2, 57.5, and 46.2%, respectively; the 3-,
5-, and 10-year OS was 89.4, 81.5, and 65.2%, respec-
tively. Patients with PNET-derived NELM had a worse 5-
year DFS and 5-year OS compared with patients who had
non-PNET-derived NELM (DFS, PNET 36.2% vs. non-
PNET 55.2%; p = 0.001 and OS, PNET 79.5% vs. non-
PNET 83.4%; p = 0.008) (Fig. 1).
A number of factors including location of the primary NET,
functional status, grade of tumor differentiation, lymph node
status, timing of primary and metastatic tumor, presence of
extrahepatic disease, and liver tumor burden were each asso-
ciated with 10-year OS (Table 2). Particularly, patients with
PNET-derived NELM had a markedly worse 10-year OS of
58.2% (95% CI, 48.2–66.9) vs. 71.6% (95% CI, 62.6–78.8)
for patients with non-PNET-derived NELM (p = 0.008).
Moreover, patients with a non-functional PNET-derived
NELM had a much worse OS of 54.8% (95% CI, 43.7–
64.5) compared with 75.0% (95% CI, 63.3–83.4) for non-
PNET-derived NELM (p < 0.001). Patients with well, moder-
ate, and poor tumor grade differentiation had a 10-year OS of
80.4% (95% CI, 71.1–87.1), 58.2% (95% CI, 40.5–72.3), and
51.9% (95% CI, 33.2–67.8), respectively (p = 0.001).
Similarly, tumor burden and site were associated with prog-
nosis. Specifically, 10-year OS was 58.4% (95% CI, 46.5–
68.6) for patients with >75% liver involvement, 66.6% (95%
CI, 53.8–76.6) for patients with 75–50% liver involvement,
71.0% (95% CI, 56.4–81.5) for patients with 50–25% liver
involvement, and 92.3% (95% CI, 56.6–99.9) for patients
with <25% liver involvement (p < 0.027). Similarly, patients
with extrahepatic disease had a worse OS of 42.8% (95% CI,
23.2–61.2) compared with 67.8% (60.8–78.7) for patients
without extrahepatic disease. On the final pathological speci-
men, presence of lymph nodemetastasis and R1-R2 resections
were associated with worse outcome (Table 2).
Propensity Score-Matched Analysis of Patients
with NELM from PNETand Non-PNET
A propensity score matching analysis was then performed to
minimize confounding and create more comparable cohorts of
Fig. 1 a Kaplan-Meier OS survival curve comparing PNET vs. non-
PNET-derived NELM NET. b Kaplan-Meier survival DFS curve
comparing PNET vs. non-PNET-derived NELM NET
Fig. 2 a Kaplan-Meier survival OS curve comparing PNET vs. non-
PNET-derived NELM NET after propensity score matching. b Kaplan-
Meier survival DFS curve comparing PNET vs. non-PNET-derived
NELM NET after propensity score matching
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patients in the PNET and non-PNET groups (Table 3). After
propensity matching for gender, grade of tumor differentia-
tion, lymph node status, functional status, synchronous dis-
ease, preoperative treatment, liver involvement, extrahepatic
disease, margin status, and adjuvant treatment, the propensity-
matched cohort included 264 patients. After propensity
matching, demographic and clinicopathologic characteristics
of the two groups were comparable, including lymph nodes
status (p = 0.66), presence of extrahepatic disease (p = 0.48),
and tumor differentiation (p = 0.09). With a median follow-up
of 5.1 years, the 5-year DFS and OS of patients with PNET-
derived NELM and non-PNET derived NELM were compa-
rable (DFS, PNET 46.2% vs. non-PNET 55.9%; p = 0.22 and
OS, PNET 81.5% vs. non-PNET 84.3%; p = 0.19) (Fig. 2). In
the multivariable Cox model, while the presence of extrahe-
patic disease and tumor grade were associated with DFS (ex-
trahepatic disease, HR 2.12, 95% CI, 1.19–3.75, p = 0.010;
tumor grade, HR 1.91, 95% CI, 1.43–2.55, p < 0.001) and OS
(extrahepatic disease, HR 3.09, 95% CI, 1.65–5.79, p < 0.001;
tumor grade, HR 1.76, 95% CI, 1.25–2.48, p = 0.001), prima-
ry tumor location was not associated with long-term outcome
(DFS, HR 0.92, 95% CI, 0.60–1.42; OS, HR 0.93, 95% CI,
0.58–1.49; both p > 0.05).
Discussion
Previously regarded as rare, the incidence of GEP-NET is
increasing worldwide ranging from 2.5 to 4.5 per 100,000.
9
The most common gastro-entero-pancreatic neuroendocrine
tumors are carcinoid, insul inomas, gastr inomas,
somatostatinomas, glucagonomas, and vipomas. NET can be
either sporadic or part of the multiple neuroendocrine neopla-
sia type 1 (MEN type 1) syndrome. While many NET are
indolent, up to 60–90% of patients develop liver metastasis
during the course of their disease.
2
Given the importance of
NELM in the natural history of NET, we sought to evaluate
the outcome of patients with NELM arising from different
primary NET sites, undergoing curative intent liver surgery,
with a particular emphasis on examining the impact of PNET
vs. non-PNET derived primary tumors. In particular, the cur-
rent study was important because we demonstrated that many
of the clinicopathological characteristics of patients with
PNET vs. non-PNET-derived NELM were different. In turn,
while the PNET primary tumor site appeared to be associated
with a worse long-term outcome, on propensity score analysis
primary tumor site was no longer associated with either DFS
or OS.
On univariable analysis, patients with PNET-derived
NELM had a worse 5-year DFS and OS compared with pa-
tients who had non-PNET-derived NELM (DFS, PNET
36.2% vs. non-PNET 55.2%; p = 0.001 and OS, PNET
79.5% vs. non-PNET 83.4%; p = 0.008). Importantly, several
baseline clinicopathological characteristics of patients with
PNET vs. non-PNET-derived NELMwere different. In partic-
ular, patients with PNET-derived NELM were more likely to
have non-functional, moderate-to-poorly differentiated tu-
mors. In contrast, patients with non-PNET-derived NELM
more often had extrahepatic disease and other characteristics
typically considered less prognostically favorable.
23
However, similar to colorectal liver metastasis, the presence
of extrahepatic disease should not be considered a strict con-
traindication to surgical resection of NELM. In fact, while the
Table 2 Univariate 10-year overall survival analysis of the study
cohort (n = 421)
Variable OS at 10 years (%) 95% CI p value
Whole cohort 65.2 58.5–70.9 –
Age 0.12
<65 years 80.9 71.6–87.5
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presence of extrahepatic disease was associated with poor
prognosis, curative intent resection in the presence of
extraheptic disease should be considered when the disease is
limited and an R0 resection is possible. The non-functional
nature of PNET-derived NELM was another factor that has
been associated with a worse prognosis.
17
Specifically,
Spolverato et al. reported aMarkov decisionmodel to estimate
and compare the cost-effectiveness associated with different
management strategies (i.e., hepatic resection vs. intra-arterial
therapy) for a simulated cohort of patients with NELM.
17
In
that study, using a lifetime horizon analysis, patients with
asymptomatic NELM had a worse overall survival after he-
patic resection.
17
Other reported clinicopathological prognostic factors of
NELM that have been associated with a poor prognosis in-
clude R1 resection margin,
24
large hepatic tumor size,
24
Table 3 Clinical and pathologic








Patients 132 132 –
Age, median (IQR) 60.8 years (50.1–71.5) 61.8 years (53.0–67.0) 0.54
Gender 0.71
Female 72 (48.9) 75 (51.0)
Male 60 (51.3) 57 (48.7)
Functional status 0.70
Non-functional 59 (52.7) 53 (47.3)
Functional 46 (50.0) 46 (50.0)
NA/missing 27 33
Grade of differentiation 0.09
Well 80 (51.3) 76 (48.7)
Moderate 33 (57.9) 24 (42.1)
Poor 19 (37.3) 32 (62.7)
Primary tumor lymph node status 0.66
N0 54 (49.5) 55 (50.5)
N1 64 (52.5) 58 (47.5)
Synchronous disease 0.31
No 45 (45.9) 53 (54.1)
Yes 87 (52.4) 79 (47.6)
Treatment before liver surgery 0.85
None 85 (49.7) 86 (50.3)
Octreotide 23 (47.9) 25 (52.1)
Chemotherapy 8 (61.5) 5 (38.5)
NA 16 16
Liver involvement 0.84
>75% 5 (50.0) 5 (50.0)
75–50% 27 (52.9) 24 (47.1)
50–25% 35 (44.9) 43 (55.1)
>25% 50 (47.6) 55 (52.4)
NA/missing 15 5
Location 0.62
Unilobar 62 (51.7) 58 (48.3)
Bilobar 70 (48.6) 74 (51.4)
Intraoperative tumor ablation 0.66
No 105 (49.5) 107 (50.5)
Yes 26 (53.1) 23 (46.9)
NA/missing 1 2
Extrahepatic disease 0.48
No 124 (50.6) 121 (49.4)
Yes 8 (42.1) 11 (57.9)
Margin status 0.83
R0 89 (48.9) 93 (51.1)
R1 25 (47.2) 28 (52.8)
R2 10 (55.6) 8 (44.4)
NA/missing 8 3
Adjuvant therapy 0.07
None 77 (50.0) 77 (50.0)
Octreotide 38 (44.7) 48 (55.3)
Chemotherapy 17 (70.8) 7 (29.2)
Disease-free survival, 5 years (95% CI) 46.2% (36.0–55.7) 55.9% (45.4–65.3) 0.22
Overall survival, 5 years (95% CI) 81.5% (72.3–87.9) 84.3% (75.5–90.1) 0.19
NA/missing not available/missing










The effect of pri-
mary tumor site has been more controversial. Most studies
have examined cohorts that were predominantly derived
from patients with either PNET or non-PNET gastrointes-
tinal NET tumors.
10–27 As such, the impact of primary tu-
mor site has not been specifically investigated as a prog-
nostic factor in many previous studies. In those studies that
have examined primary tumor site as an independent var-
iable, some reports have noted that tumor site was indeed
an important long-term prognostic factor.
18
In fact, in the
current study, we similarly noted that patients with PNET-
derived NELM had a markedly worse 10-year OS of 58.2%
(95% CI, 48.2–66.9) vs. 71.6% (95% CI, 62.6–78.8) for
patients with non-PNET-derived NELM (p = 0.008).
However, given the varied baseline characteristics of pa-
tient with PNET vs. non-PNET tumors, direct comparisons
of these cohorts may be problematic. As such, propensity
score matching was utilized to help eliminate the residual
confounding effect of other potential clinicopathological
va r i ab les tha t migh t have impacted prognos i s .
Importantly, after propensity matching, both 5-year DFS
and OS were comparable among patients with PNET and
non-PNET derived NELM (DFS, PNET 46.2% vs. non-
PNET 55.9%; p = 0.22 and OS, PNET 81.5% vs. non-
PNET 84.3%; p = 0.19). Moreover, in the multivariable
Cox model, while the presence of extrahepatic disease
and tumor grade were associated with DFS and OS, prima-
ry tumor location was not associated with long-term out-
comes. As such, the data strongly suggest that any poten-
tial effect of primary tumor site on prognosis was likely
due to differences in underlying tumor biology and not the
origin site of the tumor itself.
Our findings further define the characteristics of NELM
and the impact of the varied tumor features on prognosis after
liver resection. Patients with PNET-derived NELMwere more
likely to have non-functional disease compared with patients
who had non-PNET-derived NELM, highlighting the impor-
tance of close follow-up to early detect liver metastases.
Indeed, as noted in the current study, patients with non-
functional liver metastases may have a worse long-term
outcome.
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In addition, while a simple comparison of PNET
vs. non-PNET NELM patients suggested a worse long-term
outcome for PNET patients, on matched analysis, primary
tumor site did not impact prognosis. As such, primary tumor
location should not necessarily inform decisions around prog-
nosis and do not have an influence on survival such as other
factors including the presence of extrahepatic disease or tumor
grade.
This study has several limitations that should be considered
when interpreting the results. The study design likely resulted
in some selection bias, as with all retrospective reports. In
addition, the multi-institutional nature of the cohort that
included different centers in Europe and the USA increased
the heterogeneity of patient selection criteria and treatment for
NELM. However, the use of a large, multicenter data set in-
creased the sample size and also improved the generalizability
of the findings. Among patients with functional PNET, data
on the type of tumor (i.e., gastrinoma, insulinoma, etc.) and
hormonal levels were also not available. Moreover, in the
present study, only patients who underwent curative intent
liver surgery for NELM were included; patients who
underwent palliative surgery, systemic or non-operative
locoregional therapy were not assessed. As such, the findings
of the current study may not pertain to these other clinical
settings.
In conclusion, patients with PNET had a worse prognosis
compared with patients who had non-PNET NELM on
univariable analysis. Patients with PNET- vs. non-PNET-
derived NELM had, however, different clinicopathological
characteristics associated with their tumors. In particular, pa-
tients with PNET tumors were more likely to present with
non-functional NELM and worse tumor grade. After account-
ing for potential confounding biases on propensity-matched
analysis, primary tumor location was not associated with
prognosis.
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